No Change in Standard of Care for HPV+ Oropharyngeal Cancer No Change in Standard of Care for HPV+ Oropharyngeal Cancer

Interim results of a large phase III trial showed that patients treated with a cetuximab regimen has worse survival than those treated with cisplatin plus radiation therapy.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news